Skip to main content
SpringerLink
Log in

Intrathecal Ziconotide: Complications and Clinical Considerations

  • Chapter
  • First Online:
Challenging Cases and Complication Management in Pain Medicine

  • 1100 Accesses

Abstract

Ziconotide (Prialt) is available for intrathecal therapy for severe nociceptive and neuropathic chronic pain. It is a synthetic deviate of an omega-conotoxin, which is an N-type voltage-gated calcium channel inhibitor. It can be used alone or with combination therapy. The initial starting dose for ziconotide infusion is less than or equal to 2.4 mcg/day or 0.1 mcg/h and is recommended to be titrated slowly to help avoid adverse effects such as confusion and memory impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715–24.

    Article  PubMed  Google Scholar 

  2. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Press (US); 2011.

    Google Scholar 

  3. Johannes CB, et al. The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain. 2010;11(11):1230–9.

    Article  PubMed  Google Scholar 

  4. Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 2009;9:327–37.

    Article  PubMed  Google Scholar 

  5. Deer TR, et al. Polyanalgesic consensus conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):436–66.

    Article  PubMed  Google Scholar 

  6. Staats PS, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63–70.

    Article  CAS  PubMed  Google Scholar 

  7. Rauck R, Wallace M, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag. 2006;31(5):393–406.

    Article  CAS  Google Scholar 

  8. Wallace MS, et al. The Ziconotide nonmalignant pain study 96–002 group. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double blind, placebo-controlled clinical trial. Neuromodulation. 2006;9(2):75–86.

    Article  PubMed  Google Scholar 

  9. Wallace MS, et al. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg. 2008;106(2):628–37.

    Article  CAS  PubMed  Google Scholar 

  10. Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain. 2010;26:635–44.

    Article  PubMed  Google Scholar 

  11. PRIALT® [Package Insert]. Jazz Pharmaceuticals, Inc. Palo Alto, CA.

    Google Scholar 

  12. Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag. 2009;5:521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wallace MS, Kosek PS, Staats P, et al. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008;9:271–81.

    Article  PubMed  Google Scholar 

  14. Webster LR, Fakata KL, Charapata S, Fisher R, MineHart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med. 2008;9:282–90.

    Article  PubMed  Google Scholar 

  15. Olivera BM, Rivier J, Clark C, et al. Diversity of Conus neuropeptides. Science. 1990;249:257–63.

    Article  CAS  PubMed  Google Scholar 

  16. Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus venom peptide pharmacology. Pharmacol Rev. 2012;64(2):259–98.

    Article  CAS  PubMed  Google Scholar 

  17. Wermeling D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003;43(6):624–36.

    Article  CAS  PubMed  Google Scholar 

  18. Malmberg AB, Yaksh TL. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N-and P-type channels inhibits formalin-induced nociception. J Neurosci. 1994;14(8):4882–90.

    CAS  PubMed  Google Scholar 

  19. Simms BA, Zamponi GW. Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron. 2014;82(1):24–45.

    Article  CAS  PubMed  Google Scholar 

  20. Zamponi GW, et al. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67(4):821–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lee S. Pharmacological inhibition of voltage-gated Ca2+ channels for chronic pain relief. Curr Neuropharmacol. 2013;11(6):606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yaksh TL, et al. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation. 2012;15(6):508–19.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Gohil K, et al. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC). Brain Res. 1994;653(1):258–66.

    Article  CAS  PubMed  Google Scholar 

  24. McGuire D, et al. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol. 1997;30(3):400–3.

    Article  CAS  PubMed  Google Scholar 

  25. Pope JE, Deer TR. Ziconotide: a clinical update and pharmacologic review. Expert Opin Pharmacother. 2013;14(7):957–66.

    Article  CAS  PubMed  Google Scholar 

  26. Olivier Brenet MD, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician. 2012;15:395–403.

    PubMed  Google Scholar 

  27. Mohammed SI, et al. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study. Neuromodulation. 2013;16(6):576–82.

    Article  PubMed  Google Scholar 

  28. Saulino M, et al. Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. Eur J Phys Rehabil Med. 2009;45(1):61–7.

    CAS  PubMed  Google Scholar 

  29. Saulino M. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report. Spinal Cord. 2007;45(11):749–52.

    Article  CAS  PubMed  Google Scholar 

  30. Coffey RJ, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993;78(2):226–32.

    Article  CAS  PubMed  Google Scholar 

  31. Berde CB, Strichartz GR. Local anesthetics. In: Miller RD, Eriksson LI, Fleisher LA, et al., editors. Miller’s anesthesia. 7th ed. Philadelphia: Elsevier, Churchill Livingstone; 2009.

    Google Scholar 

  32. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation. 2005;8(4):257–63.

    Article  PubMed  Google Scholar 

  33. Shields D, Monenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007;10(Suppl 1):12–7.

    Article  PubMed  Google Scholar 

  34. Shields D, Monenegro R, Aclan J. Chemical stability of admixtures combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation. 2007;10(Suppl 1):1–5.

    Article  PubMed  Google Scholar 

  35. Shields D, Monenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 2007;10(Suppl 1):6–11.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Pain Medicine, University of California San Diego, 9300 Campus Point Drive, Mail Code 7651, La Jolla, CA, 92037, USA

    Gemayel Lee M.D. & Jeffrey Chen M.D., M.H.S.

Authors
  1. Gemayel Lee M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Chen M.D., M.H.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gemayel Lee M.D. .

Editor information

Editors and Affiliations

  1. Department of Anesthesia and Critical Care, University of Chicago Medicine, Chicago, Illinois, USA

    Magdalena Anitescu

  2. Department of Anesthesiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

    Honorio T. Benzon

  3. Division of Pain Medicine, Department of Anesthesiology, University of California San Diego School of Medicine, La Jolla, California, USA

    Mark S. Wallace

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Lee, G., Chen, J. (2018). Intrathecal Ziconotide: Complications and Clinical Considerations. In: Anitescu, M., Benzon, H., Wallace, M. (eds) Challenging Cases and Complication Management in Pain Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-60072-7_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-60072-7_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-60070-3

  • Online ISBN: 978-3-319-60072-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation